As is becoming a more common event, this week’s news posting is being composed from an airport hotel room. My NJ ASTD colleagues are networking at the Annual Technology Training Showcase in Bridgewater; I’m in Chicago watching UConn stomp Gardner-Webb in basketball – oh, well.
It’s been another noisy week in pharma, mainly with the blacker black box for Avandia (see links below).
With GSK‘s Avandia woes deepening, Takeda is about to launch an advertising blitz for Actos. Meanwhile, GSK experiments with new selling models (including fewer sales reps, of course…)
Why restrict rough product news to one Top 5 company? Sanofi‘s Acomplia gets another cloud perched over it.
Reorganization is in the air, at least in New Brunswick. Changes at J&J.
Good news Bad news for Roche. Good news – anemia drug approved by FDA! Bad news – can’t sell it…
I’m sorry. Really. Here’s a $135 million apology.
Samples for sale! Go directly to…
Forteo goes one up on Fosamax.
Door locked in Pittsburgh. Another Med. Ctr. restricts drug reps.
Not necessarily news, but a nice resource I just came across. Selling Power’s Pharmaceutical Newsletter (free registration).
Leave a Reply